HeartSciences (HSCS) EBITDA (2021 - 2026)

HeartSciences (HSCS) has 6 years of EBITDA data on file, last reported at -$1.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 18.66% year-over-year to -$1.9 million; the trailing twelve-month figure through Jan 2026 stood at -$7.8 million (up 6.2% YoY), and the FY2025 full-year result was -$8.4 million, down 32.46% from the prior year.
• EBITDA for Q1 2026 stood at -$1.9 million, up from -$2.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$1.1 million in Q1 2022 and bottomed at -$2.4 million in Q1 2025.
• The 5-year median for EBITDA is -$1.9 million (2025), against an average of -$1.7 million.
• The widest annual swing landed in 2022, when EBITDA tumbled 112.04%; it then climbed 19.17% in 2023.
• A 5-year view of EBITDA shows it stood at -$1.8 million in 2022, then climbed by 11.55% to -$1.6 million in 2023, then slipped by 26.44% to -$2.0 million in 2024, then fell by 4.45% to -$2.1 million in 2025, then rose by 6.97% to -$1.9 million in 2026.
• The last three EBITDA figures came in at -$1.9 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.

Peer Comparison